Form 4: Organon & Co. Corporate Controller Reports Stock Transactions

Kathryn DiMarco, Corporate Controller of Organon & Co., reports transactions involving common stock and restricted stock units on March 31, 2024.

Summary

• Kathryn DiMarco, the Corporate Controller of Organon & Co., filed a Form 4 detailing changes in beneficial ownership.
• On March 31, 2024, DiMarco engaged in multiple transactions involving Organon common stock and restricted stock units (RSUs).
• These transactions included the vesting of RSUs and the subsequent disposition of shares to cover tax obligations.
• Specifically, 4,294 RSUs vested, converting into common stock, and 1,471 shares were disposed of at a price of $18.8.
• Additionally, 8,503 RSUs vested, converting into common stock, and 2,913 shares were disposed of at a price of $18.8.
• Following these transactions, DiMarco directly owns 20,150 shares of Organon common stock and 17,007 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions, indicating a neutral sentiment.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading.
• Comparable companies like Teva Pharmaceutical Industries Ltd. and Viatris Inc. also have officers who regularly file Form 4s to report their stock transactions.
• The vesting schedules and RSU grants are typical compensation components for executives in the pharmaceutical industry.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they primarily reflect routine compensation-related activities.

Key Dates